Adult Dermatomyositis Externally-Led Patient-Focused Drug Development Meeting: Community Orientation Webinar
, , Dermatomyositis, Featured, News
MSU and TMA are leading the first-ever Adult Dermatomyositis Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting on June 7, 2024....
Join MSU and TMA for a Community Orientation Webinar to learn how you can participate virtually in the first-ever...
Watch the recording of this great webinar that includes excellent Q&A! Alvaro Silberstein, co-founder of "Wheel the World" joins...
Watch the MINT Clinical Trial for Myositis Patients with Interstitial Lung Disease Webinar
, , Featured, Research, Video
Watch the MINT Clinical Trial for Myositis Patients with Interstitial Lung Disease webinar with Dr. Rohit Aggarwal. This clinical...
Join Dr. Rohit Aggarwal and MSU for a webinar about The MINT Clinical Trial for Myositis Patients with Interstitial...
Priovant Therapeutics joins MSU to discuss The Valor Study for Dermatomyositis, a phase 3 clinical trial for Adult Dermatomyositis....
The VALOR Study – New Clinical Research Opportunity for Dermatomyositis
, , Dermatomyositis, Featured, Video
We hosted Priovant Therapeutics to discuss The Valor Study, a phase 3 clinical trial for adult dermatomyositis. Learn all...
Please join us for a webinar about the new VALOR study. The purpose of the VALOR Study is to...
Kezar Announces Topline Results from the PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
Watch the recording with Alexion Pharmaceuticals to learn about the Flex Study to evaluate the safety and efficacy of...
Join MSU with Sanjay Rakhade MD, PhD, Executive Medical Director at Alexion Astra Zeneca Rare Disease Unit to learn...
MSU is hosting the first FDA Listening Session on Adult Dermatomyositis on April 26, 2022. We hope the FDA will come...
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
, , Dermatomyositis, Featured, Research
Corbus releases topline results for the phase 3 study of lenabasum in dermatomyositis. While it didn't meet the primary...
Orphazyme announces topline results of Phase 2/3 trial of arimoclomol for Inclusion Body Myositis (IBM)
, , Featured, Inclusion Body Myositis (IBM), News
Learn more about the announcement from Orphazyme, communicating the topline results from the Phase 2/3 trial of arimoclomol for...
A Closer Look: Clinical Trials and the PRESIDIO Study
, , Dermatomyositis, Featured, Necrotizing Autoimmune Myopathy, Polymyositis, Video
Clinical trials are a key research tool for advancing medical knowledge and patient care. Join Kezar Life Sciences as...
Third Annual “A Day of Remembrance” a video event to honor and remember those we have lost with myositis....
Educational and engaging discussion w/ Dr. Andrew Mammen around immune-mediated necrotizing myopathy (IMNM) and the phase 2 clinical trial...
Clinical Trial of Arimoclomol in Inclusion Body Myositis during the COVID-19 Pandemic
, , Featured, Inclusion Body Myositis (IBM), News
Information from Orphazyme A/S about the Clinical Development of Arimoclomol in sIBM during the COVID-19 Pandemic. Read a statement...
Get Support!
Recently posted
-
Managing Your Expectations with Movement & Exercise with Kourage Health March 3, 2025
-
Meet Elisa Glass: MSU’s First Executive Director – Vision & Journey February 17, 2025
-
Catch the Replay: “Your Health, Your Voice: Building a Lifesaving Medical Binder” with the Three Myositis Musketeers! January 23, 2025
